SEP 10, 2013
ASRS 2013 Annual Meeting
In this interview from the ASRS 2013 Annual Meeting, Dr. Carl C. Awh discusses his study showing that genetic polymorphisms predict how patients with age-related macular degeneration (AMD) respond to antioxidants and zinc. His pharmacogenetic analysis of AREDS patients showed that about half would have done better taking a vitamin formulation other than AREDS. Patients with moderate AMD and no CFH risk alleles and with 1 or 2 ARMS2 risk alleles derived maximum benefit from zinc-only supplementation, while those with one or two CFH risk alleles and no ARMS2 risk alleles did better with antioxidant-only supplementation.